ClinicalTrials.gg
CompletedNCT05957406Updated Jul 8, 2026

SMART TRENDS Study

An interventional study of Acumen HPI Smart Alerts and Smart Trends Software and The HemoSphere advanced monitoring platform with Acumen HPI software, and Acumen IQ sensor and Acumen IQ cuff in Moderate to High-risk Noncardiac Surgery, sponsored by Becton, Dickinson and Company. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Becton, Dickinson and Company · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
296
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A multicenter, interventional, feasibility comparison with historical controls

02

Conditions studied

  • Moderate to High-risk Noncardiac Surgery
03

In context

Lead sponsor

Becton, Dickinson and Company is the lead sponsor of 61 studies on the registry; 5 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Age ≥ 18 years
  • ASA Physical Status ≥ 2
  • Elective noncardiac surgery with expected surgery duration ≥ 3 hours and expected post-operative length of stay of ≥ 3 days
  • Planned monitoring with an arterial catheter; Cohort 2: without planned arterial catheter insertion
  • General anesthesia with tracheal intubation and positive pressure ventilation

Exclusion criteria

Exclusion Criteria:

  • Inability to comply with the study intra-operative hemodynamic management algorithm such as surgeon request for relative hypotension or fluid restriction or avoidance of vasopressors
  • Planned vasopressor or inotrope infusion during surgery
  • to intra-arterial blood pressure monitoring
  • Has previously participated in the SMART TRENDS study
  • Serum creatine > 2.0 mg/dL (> 175 μmol/L) or CKD stage > 3A
  • Scheduled for intracranial or cardiac surgery
  • Patient who is known to be pregnant
  • Patients on mechanical circulatory support
  • Emergency surgery
  • Planned beach-chair positioning

Additional Exclusion Criteria for Cohort 2 only:

  • Extreme contraction of the smooth muscle in the arteries and arterioles of the lower arm and hand, such as may be present in patients with Raynaud's disease
  • Finger or hand deformity that prevents proper placement of finger cuff by visual inspection
  • Inability to place Acumen IQ finger cuffs due to subject anatomy, condition, or obstructive paraphernalia (such as false nails)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
296 participants (actual)

Study arms

  • Other
    SMART TRENDS - Acumen IQ Sensor

    Acumen HPI Smart Alerts and Smart Trends Software Feature to guide hemodynamic management in moderate-to-high-risk noncardiac surgery.

    Device: Acumen HPI Smart Alerts and Smart Trends Software

  • Other
    SMART TRENDS - Acumen IQ Cuff

    Acumen HPI Smart Alerts and Smart Trends Software Feature to guide hemodynamic management in moderate-to-high-risk noncardiac surgery.

    Device: The HemoSphere advanced monitoring platform with Acumen HPI software, and Acumen IQ sensor and Acumen IQ cuff

Interventions

  • DeviceAcumen HPI Smart Alerts and Smart Trends Software

    Device: Acumen HPI Smart Alerts and Smart Trends Software The Acumen HPI Smart Alerts and Smart Trends Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The Acumen HPI Smart Alerts and Smart Trends Software suite is enabled by the minimally invasive Acumen IQ sensor.

  • DeviceThe HemoSphere advanced monitoring platform with Acumen HPI software, and Acumen IQ sensor and Acumen IQ cuff

    Device: HemoSphere ClearSight Module and Pressure Controller, and adult Acumen IQ finger cuff

06

What researchers measure

Primary outcomes

  1. HPI Smart Alert

    The proportion of HPI Smart Alert prompts displayed resulting in initiation of action within 5 minutes consistent with an intra-operative hemodynamic management algorithm.

    Time frame: From start to end of non-cardiac surgery

07

Study locations

8 sites
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Oregon Health & Science University
    Portland, Oregon 997239, United States
  • Prisma Health
    Greenville, South Carolina 29615, United States
  • University of Washington
    Seattle, Washington 98195, United States
08

References and documents

Publications

  • Guerra-Londono CE, Hand WR, Fleming N, Davis J, Treggiari MM, Dunkman WJ, Kumar SS, Khanna AK, Yang JT, Domino KB. Hypotension prediction index smart alerts and trends to improve compliance with goal-directed hemodynamic therapy: a feasibility study. BMC Anesthesiol. 2025 Sep 30;25(1):471. doi: 10.1186/s12871-025-03336-z. PubMed 41029588 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Oct 2025, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2023
First posted
Jul 24, 2023
StartActual
Jul 11, 2023
Primary completionActual
Oct 27, 2025
CompletionActual
Oct 27, 2025
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05957406
Responsible party
Sponsor
First posted
Jul 24, 2023
Start date
Jul 11, 2023
Primary completion
Oct 27, 2025
Completion
Oct 27, 2025
Last update
Jul 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion